🟢 Beam Therapeutics Inc. trades 5.4% higher on positive BEAM-302 clinical data and accelerated FDA path potential

Beam Therapeutics Inc is trading about 5.4% up in pre-market near $31.00, driven by positive clinical news.

• News from June 7 indicated that new data from its BEAM-302 program showed sustained protective protein levels, supporting a potential accelerated FDA review path.
• The stock is rebounding from a sharp 10.5% drop on June 5.
• The positive data helps reset investor focus on the company's base editing technology after recent volatility.